Trial Profile
A first in human clinical trial of coronavirus neutralisng antibodies
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 03 Apr 2020
At a glance
- Drugs Coronavirus neutralising antibodies 3rd Peoples Hospital of Shenzhen/Brii Biosciences/Tsinghua University (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
- 03 Apr 2020 New trial record
- 31 Mar 2020 According to a Tsinghua University media release, this study is planned for third quarter this year.
Most Recent Events
Trial Overview
Purpose
This study will evaluate coronavirus neutralisng antibodies for the treatment and prevention of COVID-19 infections.
Diseases Treated
| Indication | Qualifiers | Patient Segments |
|---|---|---|
| COVID 2019 infections | prevention, treatment | - |
Subjects
- Subject Type patients
- Sex not stated
Trial Details
Organisations
- Affiliations Brii Biosciences
Trial Dates
-
Initiation Dates
Planned : 01 Jul 2020
Other Details
- Design prospective
- Phase of Trial Phase I
- Location Unknown
- Focus Adverse reactions; First in man
Interventions
| Drugs | Route | Formulation |
|---|---|---|
| Coronavirus neutralising antibodies 3rd Peoples Hospital of Shenzhen/Brii Biosciences/Tsinghua UniversityPrimary Drug | Parenteral |
-
|
Coronavirus neutralisng antibodies
Trial History
| Event Date | Event Type | Comment |
|---|---|---|
| 03 Apr 2020 | New trial record | New trial record Updated 03 Apr 2020 |
| 31 Mar 2020 | Other trial event | According to a Tsinghua University media release, this study is planned for third quarter this year. Updated 03 Apr 2020 |
References
-
Tsinghua University. Tsinghua University, 3rd Peoples Hospital of Shenzhen and Brii Biosciences Establish Partnership to Develop Neutralizing Antibodies Against COVID-19. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG